Analysis of Dapagliflozin and Empagliflozin Prescribing Patterns Based on the Clinical Profiles of Patients with Type 2 Diabetes Mellitus at Pharmacy X, Bandung
DOI:
https://doi.org/10.38035/ijphs.v4i3.2275Keywords:
Dapagliflozin, Empagliflozin, Type 2 Diabetes Mellitus, Rescribing Patterns, Clinical ProfileAbstract
Type 2 Diabetes Mellitus (T2DM) is a chronic disease with a prevalence that continues to increase annually worldwide. SGLT2 inhibitors such as dapagliflozin and empagliflozin not only effectively lower blood glucose levels but also provide cardioprotective and renoprotective benefits, as demonstrated in various clinical trials. This study aims to analyze the prescribing patterns of dapagliflozin and empagliflozin and their association with the clinical characteristics of T2DM patients at Pharmacy X in Bandung. This quantitative study with a descriptive observational design involved 60 patients selected through consecutive sampling. Data were collected through structured interviews via WhatsApp and prescription verification. Data analysis employed descriptive statistics and the Chi-Square test. The results showed that respondents were predominantly male (66.67%) and aged >65 years (41.67%). Prescribing patterns showed balanced use of dapagliflozin and empagliflozin (50.00% each), with monotherapy being the most common pattern (60.00%). The most frequent comorbidity was ASCVD (30.00%). The Chi-Square test revealed no significant association between age (p=0.96), gender (p=0.10), therapy pattern (p=0.71), or comorbidity profile (p=0.31) with the type of SGLT2 inhibitor prescribed. The study concludes that the selection of dapagliflozin or empagliflozin at Pharmacy X is not influenced by demographic characteristics or therapy patterns, but is rather determined by clinical considerations such as the patient’s cardiovascular and renal risk profile. Further studies with larger populations are needed to confirm these findings.
References
American Diabetes Association Professional Practice Committee. (2022). Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2022. Diabetes Care, 45(1), S17--S38. https://doi.org/10.2337/dc22-S002
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care, 47(Suppl 1), S158–S178. https://doi.org/10.2337/dc24-S009
American Diabetes Association Professional Practice Committee for Diabetes. (2026). 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care, 49(Supplement_1), S246–S260. https://doi.org/10.2337/dc26-S011
Azegami, T., Kaneko, H., Okada, A., Suzuki, Y., Aoyama, K., Nakayama, T., … Hayashi, K. (2025). Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real-world database study. Diabetes, Obesity and Metabolism, 27(11), 6294–6303. https://doi.org/10.1111/dom.70020
Aziz, Z., Absetz, P., Oldroyd, J., Pronk, N. P., & Oldenburg, B. (2015). A systematic review of real-world diabetes prevention programs: Learnings from the last 15 years. Implementation Science, 10(1), 172. https://doi.org/10.1186/s13012-015-0354-6
Bhat, M. H., Baba, M. S., Alam, M. E., Bhat, A. H., Mir, S., Dar, B. Q., … Sharma, P. (2024). Gender differences in the clinical profile of sodium-glucose cotransporter-2 inhibitor-related urinary tract infections. Cureus, 16(8), e67590. https://doi.org/10.7759/cureus.67590
Cowie, M. R., & Fisher, M. (2020). SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology, 17(12), 761–772. https://doi.org/10.1038/s41569-020-0406-8
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., … others. (2022). Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 65(12), 1925–1966. https://doi.org/10.1007/s00125-022-05787-2
DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2017). Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology, 13(1), 11–26. https://doi.org/10.1038/nrneph.2016.170
Dewi, I., Khotimah, H., Nasution, R., Zulpan, Z., Hariyati, T., & Rusli, A. (2025). Teori Populasi dan Pengambilan Sampel. Jurnal Literasiologi, 14(2). https://doi.org/10.47783/literasiologi.v14i2.1026
George, J., McNamara, K., & Stewart, K. (2011). The roles of community pharmacists in cardiovascular disease prevention and management. The Australasian Medical Journal, 4(5), 266. https://doi.org/10.4066/AMJ.2011.698
Hanlon, P., Butterly, E., Wei, L., Wightman, H., Almazam, S. A. M., Alsallumi, K., … McAllister, D. A. (2025). Age and sex differences in efficacy of treatments for type 2 diabetes: A network meta-analysis. Jama, 333(12), 1062–1073. https://doi.org/10.1001/jama.2024.27402
Htike, K. M., Thi, W. M., & Mahato, R. K. (2025). Understanding the burden and associated risk factors of type 2 diabetes mellitus among middle-aged and aging population in Yangon, Myanmar: A cross-sectional analytical study. Journal of Diabetes & Metabolic Disorders, 24(2), 1–10. https://doi.org/10.1007/s40200-025-01768-5
Kementerian Kesehatan RI. (2019). Laporan Nasional Riskesdas 2018. Jakarta: Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.
Kunasegaran, S., Beig, J., Khanolkar, M., & Cundy, T. (2018). Adherence to medication, glycaemic control and hospital attendance in young adults with type 2 diabetes. Internal Medicine Journal, 48(6), 728–731. https://doi.org/10.1111/imj.13808
Lin, X., Xu, Y., Pan, X., Xu, J., Ding, Y., Sun, X., … Shan, P.-F. (2020). Global, regional, and national burden and trend of diabetes in 195 countries and territories: An analysis from 1990 to 2025. Scientific Reports, 10(1), 14790. https://doi.org/10.1038/s41598-020-71908-9
Magliano, D. J., & Boyko, E. J. (2021). IDF Diabetes Atlas 2021 (10th Ed.). Brussel: International Diabetes Federation.
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., … Cannon, C. P. (2021). Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiology, 6(2), 148–158. https://doi.org/10.1001/jamacardio.2020.4511
NICE Guideline. (2026). Type 2 Diabetes in Adults: Management. London: NICE Guideline.
Paulino-Gonzalez, D., Pardiño-Vega, M. A., Andrade-Arbaiza, E., Xiloj-López, S. A., Juárez-Aldana, K. V, Cruz-Hernandez, S. E., … Navarro-Martinez, D. A. (2022). SGLT-2 Inhibitors After Acute Coronary Syndrome: A Preventive Approach for Heart Failure-Related Complications: A Meta-Analysis. American Journal of Therapeutics, pp. 10–1097. LWW. https://doi.org/10.1097/MJT.0000000000002039
Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats, A. J. S. (2022). Global burden of heart failure: A comprehensive and updated review of epidemiology. Cardiovascular Research, 118(17), 3272–3287. https://doi.org/10.1093/cvr/cvac013
Somaili, M., Oraibi, O., Mohrag, M., Hommadi, A., Moafa, E., Kulaybi, A., … Majrashi, K. (2022). Baseline characteristics associated with sodium-glucose cotransporter inhibitor prescriptions in type 2 diabetic patients in Jazan, Saudi Arabia. Cureus, 14(4), e24284. https://doi.org/10.7759/cureus.24284
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., … Bekiari, E. (2020). Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. Annals of Internal Medicine, 173(4), 278–286. https://doi.org/10.7326/M20-0864
Yang, I.-N., Chong, K.-S., Peng, Z.-Y., Ou, H.-T., & Wang, M.-C. (2025). Comparative effectiveness and prescribing patterns of dapagliflozin vs empagliflozin in type 2 diabetes patients: A target trial emulation. Diabetes Research and Clinical Practice, 228, 112427. https://doi.org/10.1016/j.diabres.2025.112427
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nadlira Dzakiah Hermawan, Rida Emelia
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish their manuscripts in this journal agree to the following conditions:
- The copyright on each article belongs to the author(s).
- The author acknowledges that the International Journal of Psycology and Healt Science (IJPHS) has the right to be the first to publish with a Creative Commons Attribution 4.0 International license (Attribution 4.0 International (CC BY 4.0).
- Authors can submit articles separately, arrange for the non-exclusive distribution of manuscripts that have been published in this journal into other versions (e.g., sent to the author's institutional repository, publication into books, etc.), by acknowledging that the manuscript has been published for the first time in the IJPHS.
